CHINOOK THERAPEUTICS INC's ticker is KDNY and the CUSIP is 16961L106. A total of 158 filers reported holding CHINOOK THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.03 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $31,672,680 | +64.9% | 824,380 | -0.6% | 0.18% | +35.1% |
| Q1 2023 | $19,208,713 | -11.6% | 829,750 | 0.0% | 0.13% | +28.4% |
| Q4 2022 | $21,739,450 | +33.4% | 829,750 | +0.1% | 0.10% | +6.2% |
| Q3 2022 | $16,300,000 | +12.3% | 829,107 | -0.1% | 0.10% | -57.1% |
| Q2 2022 | $14,512,000 | +17.5% | 829,750 | +9.9% | 0.22% | +48.3% |
| Q1 2022 | $12,348,000 | +36.6% | 754,750 | +36.2% | 0.15% | +65.9% |
| Q4 2021 | $9,040,000 | – | 554,250 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 5,161,888 | $135,241,466 | 29.11% |
| Octagon Capital Advisors LP | 2,551,703 | $66,854,619 | 10.41% |
| Affinity Asset Advisors, LLC | 818,035 | $21,432,517 | 8.40% |
| Frazier Life Sciences Management, L.P. | 4,345,559 | $113,853,646 | 7.08% |
| Saturn V Capital Management LP | 423,177 | $6,728,298 | 5.58% |
| Altium Capital Management LP | 385,000 | $10,087,000 | 5.13% |
| Deep Track Capital, LP | 3,000,000 | $78,600,000 | 3.30% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 340,389 | $8,914,788 | 2.75% |
| Vivo Capital, LLC | 872,151 | $22,850 | 2.63% |
| Nan Fung Group Holdings Ltd | 113,950 | $2,985,490 | 2.06% |